title: Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.
abstract: To control hyperphosphataemia without hyperaluminaemia, A1(OH)3, which was given in addition to high doses of oral calcium, was replaced by Mg(OH)2 for 6 months in 20 haemodialysed patients and for 20 months in 12. The treatment during the control period was 110 +/- 91 mmol/day of oral calcium element given as CaCO3 and/or Calcium Sorbisterit and 1.05 +/- 1.47 g/day of A1(OH)3. Haemodialysis treatment was 4 h, thrice weekly. To prevent hypermagnesaemia, dialysate magnesium was decreased from 0.75 mmol/l to 0.375 mmol/l. After a control period of 3 months, Mg(OH)2 was given at a mean dose of 2.6 +/- 2 g/day and oral calcium supplements were decreased to 76 mmol/day. Two subsequent bone histomorphometry studies were performed at 8 month intervals in four patients and at 20 month intervals in seven patients. The results show a good control of plasma calcium (mean +/- SD: 2.43 +/- 0.1 mumol/l); phosphate (1.76 +/- 0.4 to 1.66 +/- 0.3 mmol/l); aluminum (1.3 +/- 0.1 mumol/l to 0.6 +/- 0.1 mumol/l); alkaline phosphatase (135 +/- 65 to 125 +/- 40 IU); and PTH fragments (PTH C terminal decreased from 260 +/- 214 to 185 +/- 182 pg/ml, PTH medium from 4185 +/- 5113 to 2270 +/- 4880 pg/ml). Plasma magnesium increased from 0.96 +/- 0.2 to 1.54 +/- 0.2 mmol/l. Bone histomorphometry shows no change in mineralisation, and a borderline decrease of resorption parameters. The main side-effects are (1) diarrhoea, which was well controlled by transient treatment with karaya gum, and (2) an increased need for potassium binders.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Néphrologie, CHU Amiens, France.
authors.forename: P
authors.initials: P
authors.lastname: Morinière
authors.forename: I
authors.initials: I
authors.lastname: Vinatier
authors.forename: P F
authors.initials: PF
authors.lastname: Westeel
authors.forename: M
authors.initials: M
authors.lastname: Cohemsolal
authors.forename: S
authors.initials: S
authors.lastname: Belbrik
authors.forename: Z
authors.initials: Z
authors.lastname: Abdulmassih
authors.forename: C
authors.initials: C
authors.lastname: Hocine
authors.forename: A
authors.initials: A
authors.lastname: Marie
authors.forename: P
authors.initials: P
authors.lastname: Leflon
authors.forename: D
authors.initials: D
authors.lastname: Roche
mesh_terms: D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000008:administration & dosage* / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008274:Magnesium / Q000009:adverse effects*; D008276:Magnesium Hydroxide / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism*; D010710:Phosphates / Q000097:blood; D011137:Polystyrenes / Q000008:administration & dosage*; D006435:Renal Dialysis; D014511:Uremia / Q000378:metabolism / Q000628:therapy*
chemical_list: D008903:Minerals; D010710:Phosphates; D011137:Polystyrenes; C003321:polystyrene sulfonic acid; D002119:Calcium Carbonate; D008274:Magnesium; D008276:Magnesium Hydroxide; D002118:Calcium